50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies

Key Takeaways Explain This Topic AI

The ACC/AHA blood pressure categories (set in 2017 and unchanged in the 2025 AHA/ACC guideline) are Normal (<120/<80 mmHg), Elevated (120-129/<80 mmHg), Stage 1 Hypertension (130-139/80-89 mmHg), and Stage 2 Hypertension (>=140/>=90 mmHg); out-of-office confirmation via Ambulatory Blood Pressure Monitoring (ABPM) or Home Blood Pressure Monitoring (HBPM) is mandatory to exclude white-coat hypertension and identify masked hypertension.

The 2025 AHA/ACC guideline keeps a treatment target of <130/80 mmHg for adults with hypertension, and starts medication at >=130/80 mmHg when there is clinical CVD, diabetes, chronic kidney disease, or a PREVENT 10-year CVD risk >=7.5% (replacing the 2017 pooled-cohort ASCVD threshold of >=10%); this supersedes historical JNC-8 targets (<140/90 mmHg, or <150/90 mmHg for age >=60 without DM/CKD).

Evidence-based lifestyle modifications yield clinically meaningful systolic blood pressure reductions: the DASH dietary pattern lowers SBP by ~11 mmHg, dietary sodium restriction (<1,500-2,300 mg/day) reduces SBP by 5-6 mmHg, structured aerobic exercise lowers SBP by 5-8 mmHg, and weight loss lowers SBP by ~1 mmHg per kilogram lost.

First-line pharmacotherapy comprises thiazide-type diuretics (e.g., chlorthalidone 12.5-25 mg), ACE inhibitors or ARBs, and long-acting dihydropyridine calcium channel blockers; since the 2025 guideline, the initial class is chosen without regard to race, one agent is started for Stage 1 and two agents (preferably a single-pill combination) for Stage 2, and in CKD with albuminuria an ACEi or ARB is first-line.

Resistant hypertension is defined as blood pressure >=130/80 mmHg despite adherence to 3 maximally tolerated antihypertensive agents of different classes (including a diuretic), or controlled BP requiring >=4 medications; following exclusion of pseudoresistance and secondary causes (OSA, primary aldosteronism, renal artery stenosis), the fourth-line agent of choice is the mineralocorticoid receptor antagonist spironolactone (25-50 mg daily).

Last updated: October 2026

Blood Pressure Classification & Diagnostic Framework

Hypertension is the leading preventable contributor to premature cardiovascular morbidity, stroke, heart failure, and end-stage kidney disease worldwide. In 2017, the American College of Cardiology and American Heart Association (ACC/AHA) fundamentally redefined blood pressure (BP) staging, lowering diagnostic thresholds to facilitate earlier lifestyle and pharmacologic intervention before irreversible vascular remodeling occurs. The 2025 AHA/ACC guideline , which replaces the 2017 guideline, keeps the same blood pressure categories.

ACC/AHA Blood Pressure Categories (2017, unchanged in 2025)

Blood pressure categories in non-pregnant adults aged 18 years and older are classified based on the average of two or more properly measured seated blood pressure readings obtained on two or more separate clinical encounters: ACC/AHA BLOOD PRESSURE CLASSIFICATION (2017 = 2025)

• Category Systolic BP (mmHg) Diastolic BP (mmHg)
• ═════════════════════════════════════════════════════════════════════════════
• Normal < 120 AND < 80
• Elevated 120 to 129 AND < 80
• Stage 1 Hypertension 130 to 139 OR 80 to 89
• Stage 2 Hypertension >= 140 OR >= 90
• Hypertensive Crisis > 180 AND/OR > 120
• ═════════════════════════════════════════════════════════════════════════════
• *Note: If systolic and diastolic readings fall into different stages, the higher

category dictates clinical staging and therapeutic decision-making.

Hypertensive Urgency vs. Emergency :

Hypertensive Urgency : Severe elevation (SBP >180 mmHg and/or DBP >120 mmHg) in an asymptomatic patient without acute target organ damage . Managed in the outpatient setting by adjusting or re-initiating oral antihypertensive medications; rapid parenteral BP lowering is contraindicated because abrupt hypoperfusion can precipitate ischemic stroke or acute myocardial infarction.

Hypertensive Emergency : Severe elevation associated with acute, ongoing target organ damage (acute pulmonary edema, acute coronary syndrome, aortic dissection, acute ischemic stroke, intracerebral hemorrhage, hypertensive encephalopathy, acute kidney injury, or eclampsia). Requires immediate intensive care admission and titrated intravenous antihypertensive therapy (e.g., nicardipine, labetalol, clevidipine, nitroprusside), aiming for a controlled reduction of mean arterial pressure by no more than 20% to 25% within the first hour (with the critical exception of acute aortic dissection, where rapid reduction of SBP to <120 mmHg within 20 minutes is mandatory).

Office Blood Pressure Measurement Protocol

Spurious blood pressure readings are exceptionally common in routine primary care. Adherence to a standardized measurement protocol is vital:

Patient Preparation : The patient must rest quietly seated in a chair for at least 5 minutes before measurement. Avoid caffeine, exercise, and smoking for at least 30 minutes. Ensure the urinary bladder is empty.

Proper Positioning : Patient seated with feet flat on the floor, back supported, legs uncrossed, and the measurement arm bare and supported at heart level (the mid-point of the sternum). Supporting the arm below heart level falsely elevates readings; crossing legs elevates systolic pressure by 2 to 8 mmHg.

Cuff Sizing : The cuff bladder length must encircle 75% to 100% of the patient's arm circumference, and the bladder width must encircle at least 40% of the arm circumference. An undersized cuff produces falsely elevated blood pressure readings ("cuff hypertension").

Technique : Use a validated automated oscillometric device. Measure in both arms at the initial visit; if a consistent inter-arm discrepancy >10-15 mmHg exists, the higher arm reading is used for future management, and subclavian stenosis or coarctation of the aorta must be considered.

Out-of-Office Confirmation: ABPM & HBPM

Because in-office readings frequently misclassify patients, the ACC/AHA and US Preventive Services Task Force (USPSTF) strongly recommend confirming the diagnosis of hypertension with out-of-office blood pressure monitoring before initiating chronic pharmacotherapy, unless the patient presents with Stage 2 HTN (BP >=140/90 mmHg) accompanied by established target-organ damage (LVH, retinopathy, CKD). OUT-OF-OFFICE BLOOD PRESSURE DIAGNOSTIC THRESHOLDS

• Modality Daytime (Awake) Nighttime (Asleep) 24-Hour Average
• ─────────────────────────────────────────────────────────────────────────────────────────────
• Ambulatory BP Monitoring (ABPM) >= 130/80 mmHg >= 110/65 mmHg >= 125/75 mmHg
• Home BP Monitoring (HBPM) >= 130/80 mmHg N/A >= 130/80 mmHg
• ─────────────────────────────────────────────────────────────────────────────────────────────

Ambulatory Blood Pressure Monitoring (ABPM) :

The clinical gold standard for out-of-office assessment. The automated device records blood pressure every 15 to 30 minutes over a continuous 24-hour cycle.

Evaluates nocturnal dipping : In healthy individuals, blood pressure drops by 10% to 20% during sleep. "Non-dipping" (<10% nocturnal drop) or "reverse dipping" (nighttime BP exceeding daytime BP) is a powerful independent predictor of adverse cardiovascular mortality, stroke, and chronic kidney disease.

Home Blood Pressure Monitoring (HBPM) :

Practical, highly accessible alternative using a validated, automated upper-arm cuff device.

Protocol: Measure twice daily (morning before breakfast and medications; evening before dinner/bedtime), taking two consecutive readings 1 minute apart each time, for 7 consecutive days . The readings from day 1 are discarded, and the remaining 12 readings are averaged.

White-Coat Hypertension vs. Masked Hypertension :

White-Coat Hypertension : Office BP >=130/80 mmHg, but out-of-office readings are consistently normal (ABPM daytime <130/80 mmHg or HBPM average <130/80 mmHg). Occurs in 15% to 30% of patients. Management focuses on lifestyle interventions and annual ABPM/HBPM reassessment; antihypertensive pharmacotherapy is generally withheld unless high-risk target organ damage is identified.

Masked Hypertension : Office BP is normal (<130/80 mmHg), but out-of-office readings are elevated (ABPM daytime >=130/80 mmHg or HBPM >=130/80 mmHg). Occurs in 10% to 25% of adults, disproportionately in smokers, individuals with high workplace stress, and diabetics. Masked hypertension confers a cardiovascular event risk similar to sustained hypertension; pharmacotherapy is indicated .

• Treatment Thresholds, Targets & Lifestyle Interventions
• Treatment Thresholds & BP Targets: 2025 AHA/ACC vs. JNC-8

The 2025 AHA/ACC guideline uses a cardiovascular risk-stratified strategy based on the PREVENT equations (10-year total CVD risk >=7.5%), which replace the pooled cohort equations (10-year ASCVD risk >=10%) used in 2017: 2025 AHA/ACC PHARMACOTHERAPY INITIATION THRESHOLDS

• Clinical Scenario When to Start Drugs Target BP Goal
• ═════════════════════════════════════════════════════════════════════════════════════════
• Elevated BP (120-129 / <80) Lifestyle only < 120 / < 80 mmHg
• Stage 1 HTN (130-139 / 80-89) Lifestyle + 1 Medication < 130 / < 80 mmHg
• WITH clinical CVD*, diabetes, CKD,
• or PREVENT 10-yr CVD risk >=7.5%
• Stage 1 HTN (130-139 / 80-89) Lifestyle for 3-6 months, < 130 / < 80 mmHg
• WITHOUT those (PREVENT risk <7.5%) then 1 Medication if BP
• remains >=130/80
• Stage 2 HTN (>=140 / >=90) Lifestyle + 2 Medications < 130 / < 80 mmHg
• (single-pill combination)
• ═════════════════════════════════════════════════════════════════════════════════════════
• *Clinical CVD includes coronary heart disease (ACS, prior MI, stable angina, revascularization),

stroke or transient ischemic attack (TIA), heart failure, or peripheral artery disease.

Comparison with Historical JNC-8 Guidelines :

The Eighth Joint National Committee (JNC-8) established more lenient targets: <140/90 mmHg for the general population younger than 60 years, all diabetics, and all CKD patients; and a target of <150/90 mmHg for adults aged 60 years and older without diabetes or CKD .

The landmark SPRINT trial (Systolic Blood Pressure Intervention Trial) challenged JNC-8 by randomizing high-risk non-diabetic hypertensive adults to intensive treatment (target SBP <120 mmHg) versus standard treatment (target SBP <140 mmHg). Intensive treatment demonstrated a 25% relative reduction in major cardiovascular composite events and a 27% relative reduction in all-cause mortality , providing the foundational evidence for the ACC/AHA target of <130/80 mmHg (set in 2017 and kept in 2025).

Evidence-Based Non-Pharmacologic Lifestyle Modifications

Non-pharmacologic therapy is the cornerstone of blood pressure management. In Stage 1 hypertensive patients with a PREVENT 10-year CVD risk <7.5% and no clinical CVD, diabetes or CKD, lifestyle modifications are tried for 3 to 6 months, and one medication is started if BP remains >=130/80 mmHg. In patients requiring pharmacotherapy, lifestyle interventions significantly enhance drug efficacy and reduce medication burden. EVIDENCE-BASED LIFESTYLE INTERVENTIONS & SBP REDUCTION

• Intervention Specific Clinical Recommendation Expected SBP Drop
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• DASH Dietary Pattern Diet rich in fruits, vegetables, whole grains, ~ 11 mmHg
• low-fat dairy; reduced saturated and total fat

• Weight Loss Achieve healthy BMI (18.5 to 24.9 kg/m²); ~ 1 mmHg per 1 kg
• aim for >=5% body weight reduction weight lost (~5 mmHg)

• Aerobic Physical Activity 90 to 150 minutes/week of moderate-intensity ~ 5 to 8 mmHg
• aerobic exercise (65-75% heart rate reserve)

• Dietary Sodium Restriction Optimal target < 1,500 mg/day; at least aim for ~ 5 to 6 mmHg
• a reduction of >=1,000 mg/day from baseline

• Dynamic Resistance Exercise 90 to 150 minutes/week of resistance training ~ 4 to 5 mmHg
• (3 sessions/week, 60-80% 1-rep max)

• Enhanced Dietary Potassium Dietary potassium intake 3,500 to 5,000 mg/day ~ 4 to 5 mmHg
• (contraindicated in advanced CKD / hyperkalemia)

• Alcohol Moderation Limit consumption to <= 2 standard drinks/day ~ 4 mmHg
• for men, <= 1 standard drink/day for women
• ═════════════════════════════════════════════════════════════════════════════════════════════════

• First-Line Pharmacotherapy & Population-Specific Strategies
• The Three First-Line Antihypertensive Drug Classes

Robust clinical trial evidence demonstrates that cardiovascular event reduction is overwhelmingly driven by the magnitude of blood pressure lowering itself. Three primary drug classes represent proven first-line therapies for primary essential hypertension: FIRST-LINE ANTIHYPERTENSIVE DRUG CLASSES & MONITORING

Drug Class Representative Agents Key Adverse Effects Critical Monitoring / Contraindications

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Thiazide / Chlorthalidone (12.5-25 mg) Hypokalemia, hyponatremia, Check BMP at 2 to 4 weeks.

Thiazide-like Hydrochlorothiazide (25-50) hyperuricemia (gout flare), Decreased efficacy if eGFR <30 mL/min;

Diuretics hyperglycemia, hypercalcemia Chlorthalidone preferred over HCTZ.

• ACE Inhibitors Lisinopril (10-40 mg daily) Dry bradykinin cough (5-20%), Check BMP at 2 to 4 weeks; hold if
• Enalapril, Ramipril angioedema, hyperkalemia, Cr rises >30%. STRICTLY CONTRAINDICATED

acute renal decline (azotemia) in pregnancy & bilateral renal artery stenosis.

• ARBs Losartan (50-100 mg daily) Hyperkalemia, azotemia Check BMP at 2 to 4 weeks; no bradykinin
• Valsartan, Olmesartan (NO bradykinin cough; rare cough; lower angioedema risk; STRICTLY

angioedema) CONTRAINDICATED in pregnancy.

• Dihydropyridine Amlodipine (5-10 mg daily) Dose-dependent peripheral Monitor for dependent ankle edema
• CCBs Nifedipine ER (30-90 mg) edema (pre-capillary leak), (add ACEi/ARB to promote post-capillary

headache, reflex tachycardia venodilation); no routine lab monitoring.

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Pharmacologic Nuances & Trial Evidence

Chlorthalidone vs. Hydrochlorothiazide (HCTZ) :

Chlorthalidone is a thiazide-like diuretic possessing a plasma half-life of 40 to 60 hours and a large volume of distribution into erythrocytes, providing consistent, round-the-clock 24-hour blood pressure reduction.

In contrast, HCTZ has a short half-life of 6 to 12 hours, frequently resulting in loss of blood pressure control overnight and in the early morning hours.

Landmark trials that demonstrated significant reductions in cardiovascular events and stroke (such as ALLHAT and SHEP) utilized chlorthalidone , making it the guideline-preferred thiazide agent. However, chlorthalidone carries a higher propensity for hypokalemia and hyponatremia than low-dose HCTZ, necessitating baseline and follow-up serum electrolyte monitoring at 2 to 4 weeks.

ACE Inhibitors vs. ARBs :

Mechanism of Cough : ACE inhibitors prevent the breakdown of bradykinin and substance P in pulmonary tissue. Bradykinin accumulation irritates airway sensory fibers, inducing a dry, hacking, intractable cough in up to 20% of patients. ARBs selectively block the angiotensin II type 1 (AT1) receptor without inhibiting angiotensin-converting enzyme, preventing bradykinin accumulation and virtually eliminating the dry cough.

Angioedema : ACE inhibitors carry a 0.1% to 0.7% incidence of life-threatening angioedema (submucosal swelling of the tongue, lips, pharynx, and larynx), which occurs 3 to 4 times more frequently in Black individuals. ARBs carry a cross-reactivity rate of <5% for angioedema and should be used with extreme caution or avoided if prior ACEi angioedema was severe.

Renal Function Monitoring : Following ACEi or ARB initiation, dilation of the renal efferent arteriole reduces intraglomerular hydrostatic capillary pressure. A mild increase in serum creatinine of up to 30% above baseline is hemodynamically expected and acceptable , representing preservation of long-term nephron architecture. If serum creatinine rises >30%, the medication must be temporarily held and bilateral renal artery stenosis investigated.

Dual RAAS Blockade : Concurrent use of an ACE inhibitor with an ARB (or direct renin inhibitor) is strictly contraindicated (proven in the ONTARGET and ALTITUDE trials to cause increased rates of acute kidney injury, severe hyperkalemia, and syncope without any cardiovascular benefit).

Dihydropyridine CCBs & Peripheral Edema :

Dihydropyridine CCBs (amlodipine) promote selective, potent relaxation of pre-capillary precapillary arteriolar smooth muscle without dilating post-capillary venules. The resulting intracapillary hydrostatic pressure elevation forces fluid transudation into the interstitial tissue of the lower extremities, producing dependent peripheral edema.

This peripheral edema is a local physical transudate, not whole-body fluid overload or heart failure . Loop diuretics are completely ineffective. The addition of an ACE inhibitor or ARB causes post-capillary venodilation, equalizing transcapillary hydrostatic pressures and dramatically relieving amlodipine-induced edema.

Initial Drug Selection: Race-Neutral Since 2025

Race no longer guides the first drug : The 2025 AHA/ACC guideline removed race-based first-line recommendations. Adults without a compelling indication start a thiazide-type diuretic, ACE inhibitor, ARB, or long-acting dihydropyridine CCB , regardless of race or ethnicity. (The 2017 guideline recommended a thiazide or CCB for Black adults without CKD, based largely on ALLHAT subgroup data.)

Chronic Kidney Disease :

In patients with CKD Stage 3 or higher (eGFR <60 mL/min/1.73m²) OR CKD with albuminuria (UACR >=300 mg/g, or >=30 mg/g in diabetics), initial therapy must include an ACE inhibitor or ARB to slow diabetic and non-diabetic nephropathy progression.

Initiation Strategy: Monotherapy vs. Upfront Combination :

Monotherapy : One first-line agent for Stage 1 hypertension (130-139/80-89 mmHg) when medication is indicated.

Upfront Combination Therapy : For Stage 2 hypertension (>=140/90 mmHg) , the 2025 guideline recommends starting two first-line agents of different classes , preferably as a single-pill combination (e.g., CCB + ACEi, or thiazide + ARB), which improves adherence and shortens the time to blood pressure control.

• Resistant Hypertension & Secondary Hypertension Evaluation
• Definition of Resistant Hypertension

Resistant hypertension is formally defined when a patient satisfies either of the following criteria:

Blood pressure remains uncontrolled (>=130/80 mmHg) despite confirmed concurrent adherence to three antihypertensive agents of different complementary classes at maximally tolerated doses, one of which must be a diuretic ; OR

Blood pressure requires four or more antihypertensive medications to achieve therapeutic control (controlled resistant hypertension).

Step 1: Rule Out Pseudoresistance

Prior to embarking on expensive secondary diagnostic workups, clinicians must systematically exclude pseudoresistance:

Medication Non-Adherence : Present in up to 50% of patients with apparent resistant hypertension. Inquire empathetically about dosing frequency, adverse effects, and medication cost; consider supervised pill ingestion or pharmacy fill-history verification.

White-Coat Effect : Up to 30% of apparent resistant cases represent white-coat hypertension. Confirm persistently elevated out-of-office blood pressures via 24-hour ABPM or 7-day HBPM.

Inaccurate Office Technique : Ensure appropriate cuff size; using a standard adult cuff on a large or obese arm overestimates systolic BP by 10 to 30 mmHg.

Interfering Substances : Screen for and discontinue offending exogenous substances:

Nonsteroidal Anti-inflammatory Drugs (NSAIDs): induce renal sodium retention and inhibit vasodilatory prostaglandins, elevating SBP by 3 to 6 mmHg;

• Oral decongestants (pseudoephedrine, phenylephrine);
• Systemic corticosteroids;
• Oral contraceptive pills (estrogen-containing);
• Stimulants (amphetamines, methylphenidate, cocaine);
• Excessive alcohol consumption;

Herbal supplements (licorice [glycyrrhizic acid inhibits 11-beta-HSD2, causing apparent mineralocorticoid excess], ephedra, yohimbine).

Step 2: Systematic Screening for Secondary Hypertension

Secondary hypertension accounts for 5% to 10% of all hypertensive adults and up to 20% to 30% of patients with confirmed resistant hypertension. Clinical clues warranting workup include: early onset (<30 years) without family history, sudden severe worsening of previously controlled hypertension, abrupt onset of Stage 2 HTN in older adults (>=55 years), hypertensive emergency, or hypokalemia. DIAGNOSTIC WORKUP FOR SECONDARY HYPERTENSION

• Secondary Etiology Clinical Hallmarks & Clues Initial Screening Test
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Obstructive Sleep Obesity, snoring, witnessed apneas, STOP-Bang questionnaire;
• Apnea (OSA) daytime somnolence; MOST COMMON CAUSE Overnight polysomnography

• Primary Aldosteronism Spontaneous or diuretic-induced Morning plasma aldosterone
• (Conn Syndrome) hypokalemia; metabolic alkalosis; concentration (PAC) and plasma renin
• adrenal incidentaloma; family history activity (PRA): ARR >20-30 with
• of early stroke PAC >15 ng/dL suggests diagnosis

• Renal Artery Stenosis Atherosclerotic: older, generalized CVD, Renal duplex Doppler ultrasound;
• (Renovascular HTN) flash pulmonary edema, AKI on ACEi. CT angiography (CTA) or
• Fibromuscular Dysplasia (FMD): young MR angiography (MRA) of renal arteries
• female (<50 yo), carotid/abdominal bruit

• Chronic Kidney Elevated creatinine, reduced eGFR, Serum creatinine, eGFR, urinalysis
• Disease (Parenchymal) proteinuria, hematuria, small kidneys with micro, spot urine albumin-to-
• creatinine ratio (UACR)

• Cushing Syndrome Moon facies, central obesity, buffalo 24-hour urinary free cortisol;
• hump, violaceous striae >1 cm, proximal 1 mg overnight dexamethasone
• muscle weakness, hyperglycemia suppression test; late-night salivary

• Pheochromocytoma Classic triad: paroxysmal headaches, Plasma free metanephrines OR
• profuse diaphoresis, palpitations; 24-hour urinary fractionated
• labile severe hypertension, tremors metanephrines and catecholamines

• Coarctation of Aorta Upper extremity hypertension with Echocardiography; bilateral upper
• diminished/delayed femoral pulses; and lower extremity blood pressures
• brachial-femoral pulse lag; rib notching (brachial-ankle gradient >20 mmHg)
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Fourth-Line Pharmacotherapy: The PATHWAY-2 Trial

When true resistant hypertension persists despite maximal doses of an ACEi/ARB, a dihydropyridine CCB, and a thiazide diuretic, what is the optimal fourth-line agent?

The landmark PATHWAY-2 trial provided definitive, class-1 evidence: the addition of a Mineralocorticoid Receptor Antagonist (MRA) , specifically Spironolactone (25 to 50 mg daily) , is significantly superior to placebo, alpha-blockers (doxazosin), or beta-blockers (bisoprolol) in reducing blood pressure in resistant hypertension.

Pathophysiology: Resistant hypertension is predominantly maintained by occult sodium retention and unrecognized aldosterone excess.

Clinical Monitoring & Safety Rules :

Spironolactone therapy can be safely initiated if baseline serum potassium is <=4.5 mEq/L and eGFR is >=45 mL/min/1.73m² .

Recheck serum electrolytes and renal function at 1 to 2 weeks and 4 weeks after initiation.

Adverse effects: Spironolactone non-selectively binds androgen and progesterone receptors, causing dose-dependent gynecomastia , mastodynia, and erectile dysfunction in 5% to 10% of men. If antiandrogenic side effects occur, switch to Eplerenone (50 to 100 mg daily), a selective MRA with minimal affinity for sex steroid receptors, or Amiloride (10 to 20 mg daily), an epithelial sodium channel (ENaC) blocker.

Loading diagram... Clinical Algorithm for Hypertension Diagnosis, Staging & Resistant HTN Management